Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia (BPH)

Benign prostate hyperplasia (BPH) is a disease that affects over 15 million males in the U.S. and is characterized by smooth muscle proliferation in the prostate that can lead to lower urinary tract symptoms (LUTS), including urinary frequency, urgency (particularly at night) and incontinence which can have a significant impact on quality of life.

Management of BPH has historically involved medications, lifestyle modifications, and regulating dietary and fluid intake and output. Those patients who are refractory to these treatments have been referred for transurethral resection of the prostate (TURP), which is currently the gold standard definitive treatment for BPH. However, this procedure does come with significant risks including bleeding and nerve damage potentially leading to impotence. As a result, alternative options have been explored, although a number of these new techniques have not been proven to be as effective as TURP.

Prostate Artery Embolization (PAE)

The multidisciplinary Interventional Urology team at Mount Sinai includes both Interventional Radiologists and Urologists. Together, we have studied and now perform a highly effective and minimally invasive treatment for BPH called PAE (Prostate Artery Embolization). PAE is a FDA approved minimally invasive technique that can be used as an alternative to TURP with less adverse effects and increased patient comfort. A tiny catheter is navigated into the arteries feeding the prostate gland from a pinhole in either the wrist or the groin artery and small gelatin particles are injected into these small arteries to decrease blood flow to the enlarged prostate gland. The procedure can be done without overnight admission to the hospital and patients can go home the same day with very little discomfort. This innovative therapy involves new technologies, such as 3D navigation, microcatheters and state of the art x-ray imaging devices. Our center has been involved with the pivotal trials leading to the development and approval of this new technique to treat this disease without surgery. Our multidisciplinary team continues to innovate and develop this new procedure and serves as a center of excellence for continued research and trials related to PAE.